3:17-cv-06375 | MITSUBISHI TANABE PHARMA CORPORATION et al v. INVAGEN PHARMACEUTICALS, INC., | RPX Insight

MITSUBISHI TANABE PHARMA CORPORATION et al v. INVAGEN PHARMACEUTICALS, INC., DC
- 3:17-cv-06375
- D.N.J.
- Judge: Freda L. Wolfson +1
- Filed: 08/23/2017
- Closed: 06/10/2019
- Latest Docket Entry: 06/01/2020
- PACER
- Docket updated daily

5

Plaintiffs

1

Defendant

3

Accused Products

1

Patent-in-Suit

657

Days in Litigation

Docket (45 Entries)

MITSUBISHI TANABE PHARMA CORPORATION et al v. INVAGEN PHARMACEUTICALS, INC., DC
- 3:17-cv-06375
- D.N.J.
- Judge: Freda L. Wolfson +1
- Filed: 08/23/2017
- Closed: 06/10/2019
- Latest Docket Entry: 06/01/2020
- PACER
- Docket updated daily

Docket (45 Entries)

Litigation Complaint | RPX Insight

View Complaint

Cause of Action

Infringement

Market Sector

Biotech and Pharma

Court

District of New Jersey

Referred Judge

Douglas E. Arpert

Assigned Judge

Freda L. Wolfson

Outcome Summary

View Outcome Details

Validity and Enforceability Details

Infringement Details

Patent Information

Patents-in-Suit

Validity & Enforceability

US 7,943,788 B2 Enforceable

1 Detail

Claim	Outcome
All challenged claims	Enforceable and Valid Entry 37 Entry 24

Infringement

Aurobindo Pharma USA Incorporated

1 Detail

Accused Product	Patent #	Claim #	Outcome
Generic 150 mg/500 mg canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/1 g canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/500 mg canagliflozin and metformin hydrochloride tablets	US 7,943,788 B2	All Asserted Claims	Infringement Entry 24

Invagen Pharmaceuticals Incorporated

1 Detail

Accused Product	Patent #	Claim #	Outcome
Generic 150 mg/500 mg canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/1 g canagliflozin and metformin hydrochloride tabletsGeneric 50 mg/500 mg canagliflozin and metformin hydrochloride tablets	US 7,943,788 B2	All Asserted Claims	Infringement Entry 37